Cornerstone Pharmaceuticals is a pharmaceutical research company that conducts cancer research. This company's discoveries include CPI-613, a drug in Phase I/II clinical trials that targets enzymes involved in cancer cell metabolism, and Emulsiphan, which is used to improve the safety and effectiveness of current cancer therapies.